Andrew Huberman - Robin Carhart-Harris

1) Dr. Robin Carhart-Harris discusses the science behind psychedelics for mental health and their potential benefits for people with psychosis. He also discusses the potential implications of psychedelics being under the category of psychotomimetics, and their potential impact on the psychology of people with psychosis.

2) Dr. Robin discusses the use of psychedelics for mental health. He defines psychedelics as compounds that work on a particular receptor in the brain, and that can reveal something about the mind that couldn't be revealed otherwise. He also mentions that the example of blindsight is interesting but different from blindsight which is referring to non-conscious processing.

3) Dr. Robin discusses the importance of psychedelics for mental health, and the clinical trials that have been conducted with psychedelics.

4) Robin talks about a study that was done with LSD, with a focus on improving mood. However, the study was not compellingly successful and the speaker does not believe that microdosing is an effective way to improve mood.

5) Dr. Robin talks about the research that has been done with psychedelics for mental health. He discusses the different types of psychedelics that have been studied and the results that have been achieved. He also talks about the potential side effects that can occur during a psychedelic session and how those can be treated.

6) Robin discusses the science of psychedelics for mental health and how they may be helpful for people with mental health conditions. He argues that some experiences, such as the Psychedelic experience, are more important than others and that this can determine whether a person receives the therapy they need.

7) Dr. Robin discusses how the use of psychedelics for mental health can be beneficial for patients. He emphasizes the importance of trust in the experience and how this can be facilitated throughguided experience.

8) Dr. Robin talks about how trust is important for Psychedelic therapy and how it can be a predictor of response in a study of Psychedelic therapy.

9) Dr. Robin talks about the effects of psychedelics on communication, and how this can be beneficial for mental health.

10) Robin explains how some models that identify the location of the 2A receptor and look at the effects ofPsychedelics on neural activity can help to recreate the subjective experience of hallucinations. Additionally, he discusses a potential problem with this approach - that it could lead to the activation of other receptors without any changes inSubjective experience.

11) Dr. Robin Carhart-Harris discusses the benefits and drawbacks of psychedelic drugs for mental health. He also discusses the research that has been conducted on psychedelic drugs and their relationship to mental health outcomes.

12) Robin is speaking about how people can be passy in their analytical thinking and how microdoses of psychedelics could help improve well-being.4

13) Dr. Robin discusses how people can maximize neuroplasticity and brain changes following psychedelic therapy. He also describes how the integration phase can last for up to six weeks.

14) Dr. Robin discusses the science of psychedelics for mental health. He talks about how they can be used to help people process trauma and depression, and how they can be used in a therapeutic setting. He also discusses how they might be helpful in the context of first-time use.

15) Robin discusses a study in which healthy volunteers were given a placebo and awhopping dose of psilocybin, which had the effect of increasing the informational complexity of ongoing brain activity. Additionally, the study found that the bigger the trip, the bigger the synthropic brain effect.

16) Dr. Robin discusses the significance of changes in brain anatomy in people who experience psychedelic drugs, such as psilocybin. He also discusses the importance of using a cognitive flexibility paradigm to measure changes in cognition.

17) Dr. Robin discusses the study they are currently conducting with eight participants using psilocybin to treat Fibromyalgia. They are finding great success with the drug, but are careful not to over-exaggerate the findings.

18) Carhart-Harris discuss the distinction between MDMA therapy and classic psychedelics, as well as the role of eye masks in the therapy. They also discuss the importance of pre-trial expectancy in the therapy process.

19) Dr.Robin discusses the science of psychedelics and their potential effects on mental health. She discusses the fact that pre-trial expectancy and response we saw was not related to pre-trial expectancy when high, and that LSD does not have a traditional psychedelic dose.

20) Robin describes a student's experience with LSD and MDMA. The student said that they found the LSD to be very short and expensive, while the MDMA was much longer and more expensive. The student suggests that combining psychedelics and MDMA could be a way to improve results.

21) Dr. Robin discusses the science of psychedelics for mental health and their potential benefits for PTSD. He also discusses the drawbacks of using psychedelics recreationally, and how combining them with traditional therapy can offer advantages in certain patients.

22) Robin discusses the idea that the classic psychedelics, such as LSD, may offer a way to get right up next to trauma and experience relief. He also discuss the potential effects of DMT, and how it may be a better option than traditional psychedelics for veterans with issues such as traumatic brain injury.

23) Dr. Robin Carhart-Harris discusses the current state of legality of psychedelics and their potential applications in the treatment of depression, anxiety, and other conditions. He also mentions that there are a lot of therapists that are accessing psychedelics illegally, and that people should be careful getting them from unknown sources.

24) Dr. Robin discusses the current state of psychedelics and their potential use for mental health. He also talks about the importance of licensure for Psychedelics and how it could roll out soon.

25) Robin discussing MDMA andPsychedelics for Mental Health refers to a set of issues that are currently facing the FDA in regards to providing this type of treatment. They suggest that the FDA should allow MAPS, a mental health professional, to provide the treatment.

26) Robin discusses the importance of small, investigator-led studies in the field of psychiatric disorders and how they can provide valuable information about potential treatments.

27) Dr. Robin discusses the importance of psychedelics for mental health and their potential benefits, as well as the need for research on the effects of psychedelics.